When deciding whether to recommend an immunotherapy agent, it is important to ensure that the drug is approved for the specific indication. In addition, because an immunotherapy agent can take several weeks to have an effect, it is important to consider the pace of the patient’s disease progression, says Andrew L. Pecora, MD.
Biomarkers are an essential part of decision making, although some biomarkers have not been found to be absolutely predictive. The greater number of mutations a cancer has, however, the greater the likelihood that an immuno-oncology drug will work, states Pecora.
About half of patients respond to immuno-oncology drugs when they are given in combination or sequentially, notes Pecora, and fewer when the drugs are given alone. There is some variability among the diagnostic tests, states Pecora, and there are many potential explanations. At times, the tissue sample is not representative of the tumor. Also, the microenvironment of the tumor is not static. The tumor could be leaving an inflammatory state where there would be a lot of PD-1 expression, for example, and going to a noninflammatory state. There are still many unanswered questions in terms of which biomarkers are the most important in which instances, adds Pecora.
Data analysis showed that 40% of patients who filled a prescription for Wegovy in 2021 or 2022 were still taking it a year later; both Democrats and reproductive rights organizations are pressuring the Biden administration to ensure health insurers fully cover contraception; CMS implemented Medicare changes in March that limited access to blood tests that help transplant recipients ensure their organs remain healthy.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen